Abstract
Over expression of aldehyde dehydrogenase (ALDH1A1) is one of the vital hallmarks of the self-renewal and differentiational cancer stem cells (CSCs). Till now, no selective ALDH1A1 inhibitor is commercially available in the market. So there is an urgent need to explore some novel molecules which can selectively inhibit ALDH1A1 to combat cancer. Presently, our work deals with the development of QSAR models of some theophylline-based molecules by conventional 2D-QSAR, hologram QSAR (HQSAR), and Bayesian classification modeling. The descriptors identified from these QSAR models give avenues to modulate the structure of theophylline-based compounds to a desirable biological end point. Molecular docking study reveals the selectivity of these molecules towards ALDH1A1 (PDB: 4WP7) and important binding residues (GLY 125, 458; THR 129; TRP 178; TYR 297; PHE 171, 466; VAL 174, 460; MET 175; HIS 293 etc.) for the interaction with the receptors. The current study may help to design novel compounds as selective ALDH1A1 inhibitors.
Keywords: Aldehyde dehydrogenase, theophylline-based inhibitors, QSAR, HQSAR, Bayesian modeling, molecular docking.
Current Drug Discovery Technologies
Title:Insight into the Structural Requirements of Theophylline-Based Aldehyde Dehydrogenase lAl (ALDHlAl) Inhibitors Through Multi-QSAR Modeling and Molecular Docking Approaches
Volume: 13 Issue: 2
Author(s): Sk. Abdul Amin, Nilanjan Adhikari, Shovanlal Gayen and Tarun Jha
Affiliation:
Keywords: Aldehyde dehydrogenase, theophylline-based inhibitors, QSAR, HQSAR, Bayesian modeling, molecular docking.
Abstract: Over expression of aldehyde dehydrogenase (ALDH1A1) is one of the vital hallmarks of the self-renewal and differentiational cancer stem cells (CSCs). Till now, no selective ALDH1A1 inhibitor is commercially available in the market. So there is an urgent need to explore some novel molecules which can selectively inhibit ALDH1A1 to combat cancer. Presently, our work deals with the development of QSAR models of some theophylline-based molecules by conventional 2D-QSAR, hologram QSAR (HQSAR), and Bayesian classification modeling. The descriptors identified from these QSAR models give avenues to modulate the structure of theophylline-based compounds to a desirable biological end point. Molecular docking study reveals the selectivity of these molecules towards ALDH1A1 (PDB: 4WP7) and important binding residues (GLY 125, 458; THR 129; TRP 178; TYR 297; PHE 171, 466; VAL 174, 460; MET 175; HIS 293 etc.) for the interaction with the receptors. The current study may help to design novel compounds as selective ALDH1A1 inhibitors.
Export Options
About this article
Cite this article as:
Abdul Amin Sk., Adhikari Nilanjan, Gayen Shovanlal and Jha Tarun, Insight into the Structural Requirements of Theophylline-Based Aldehyde Dehydrogenase lAl (ALDHlAl) Inhibitors Through Multi-QSAR Modeling and Molecular Docking Approaches, Current Drug Discovery Technologies 2016; 13 (2) . https://dx.doi.org/10.2174/1570163813666160429115628
DOI https://dx.doi.org/10.2174/1570163813666160429115628 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Recent Pharmacoproteomics Studies of Warfarin in the Asia-Pacific: A New Strategy for Personalized Medicine?
Current Pharmacogenomics and Personalized Medicine Preparation and Characterization of Oleanolic Acid Nanoparticles
Current Pharmaceutical Analysis Lipidomic Analysis of Glioblastoma Multiforme Using Mass Spectrometry
Current Metabolomics Aldehyde Dehydrogenase as a Marker for Stem Cells
Current Stem Cell Research & Therapy VDAC1 as a Player in Mitochondria-Mediated Apoptosis and Target for Modulating Apoptosis
Current Medicinal Chemistry Ghrelin and the Brain-gut Axis as a Pharmacological Target for Appetite Control
Current Pharmaceutical Design Nucleic Acid-Based Therapeutics for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry TREM2 and the Progression of Alzheimer’s Disease
Current Neurovascular Research Ascorbic Acid: An Old Player with a Broad Impact on Body Physiology Including Oxidative Stress Suppression and Immunomodulation: A Review
Mini-Reviews in Medicinal Chemistry Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy
Current Topics in Medicinal Chemistry Structure-Activity Relationship of Nuclear Receptor-Ligand Interactions
Current Topics in Medicinal Chemistry Jak2 Tyrosine Kinase and Cancer: How Good Cells Get HiJAKed
Anti-Cancer Agents in Medicinal Chemistry Synthesis, Structure and Application of α, β Dehydro-α-aminophosphonic and α,β-Dehydro-α-aminophosphinic Acid Derivatives
Current Organic Synthesis ABC Subfamily D Proteins and Very Long Chain Fatty Acid Metabolism as Novel Targets in Adrenoleukodystrophy
Current Drug Targets A Review on Plasmodium falciparum-Protein Farnesyltransferase Inhibitors as Antimalarial Drug Targets
Current Drug Targets Design and Synthesis of a (N-Alkylaminoalkyl-Substituted)Arylalkenylamide Drug Discovery Library
Letters in Drug Design & Discovery Perspective on Nanoparticle Technology for Biomedical Use
Current Pharmaceutical Design S-equol, a Secondary Metabolite of Natural Anticancer Isoflavone Daidzein, Inhibits Prostate Cancer Growth In Vitro and In Vivo, Though Activating the Akt/FOXO3a Pathway
Current Cancer Drug Targets Tetrazole Derivatives as Promising Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry